Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.

Cancer immunology, immunotherapy : CII - 4 Jun 2024

Shen Meiying, Chen Siyin, Han Xiaojian, Hao Yanan, Wang Junfan, Li Luo, Chen Tong, Wang Bozhi, Zou Lin, Zhang Tong, Zhang Wanli, Han Xiaxia, Wang Wang, Yu Haochen, Li Kang, Liu Shengchun, Jin Aishun

Abstract excerpt

Hotspot driver mutations presented by human leukocyte antigens might be recognized by anti-tumor T cells. Based on their advantages of tumor-specificity and immunogenicity, neoantigens derived from hotspot mutations, such as PIK3CAH1047L, may serve as emerging targets for cancer immunotherapies. NetMHCpan V4.1 was utilized for predicting neoepitopes of PIK3CA hotspot mutation. Using in vitro stimulation,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Epitopes, T-Lymphocyte

Share to HLA-A11 Antigen

Share to Immunotherapy

Share to Neoplasms

Share to Receptors, Antigen, T-Cell

Source

Open in PubMed Open full text

Identifiers

PMID: 38832948
DOI: 10.1007/s00262-024-03729-y
PMCID: PMC11150344

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.PMID 38832948Read ↗

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T-cell receptors for cancer immunotherapy targeting hotspot driver mutationsSemantic proximity Read ↗

Immunogenicity of a public neoantigen derived from mutated <i>PIK3CA</i>Semantic proximity Read ↗

PIK3CA hotspot mutation generates a shared neoantigen targetable by TCR gene therapy.Semantic proximity Read ↗

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.Semantic proximity Read ↗

Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy.Semantic proximity Read ↗

Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discoverySemantic proximity Read ↗

Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.Semantic proximity Read ↗

Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinationsSemantic proximity Read ↗

Therapeutic potential of T cell receptor targeting the HLA-A*11:01-restricted KRASG12V neoantigen without cross-recognition of the self-antigen RAB7B in solid tumorsSemantic proximity Read ↗

Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals.Semantic proximity Read ↗

T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.Semantic proximity Read ↗

Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.